Inventiva (NASDAQ: IVA)
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-27 | ||||||
REV |
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.500 | ||||||
REV | 4.963M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Inventiva (NASDAQ: IVA) through any online brokerage.
Other companies in Inventiva’s space includes: Outlook Therapeutics (NASDAQ:OTLK), IDEAYA Biosciences (NASDAQ:IDYA), Centessa Pharmaceuticals (NASDAQ:CNTA), Inovio Pharmaceuticals (NASDAQ:INO) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Inventiva (NASDAQ: IVA) was reported by HC Wainwright & Co. on Monday, November 22, 2021. The analyst firm set a price target for 42.00 expecting IVA to rise to within 12 months (a possible 364.09% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Inventiva (NASDAQ: IVA) is $9.05 last updated May 27, 2022, 7:59 PM UTC.
There are no upcoming dividends for Inventiva.
Inventiva’s H1 earnings are confirmed for Wednesday, July 27, 2022.
There is no upcoming split for Inventiva.
Inventiva is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.